The emerging landscape of peptide-based inhibitors of PCSK9

Volume: 330, Pages: 52 - 60
Published: Aug 1, 2021
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a clinically validated target for treating cardiovascular disease (CVD) due to its involvement in cholesterol metabolism. Although approved monoclonal antibodies (alirocumab and evolocumab) that inhibit PCSK9 function are very effective in lowering cholesterol, their limitations, including high treatment costs, have so far prohibited widespread use. Accordingly, there is great interest in...
Paper Details
Title
The emerging landscape of peptide-based inhibitors of PCSK9
Published Date
Aug 1, 2021
Volume
330
Pages
52 - 60
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.